Impact of Nesiritide on Renal Function in Patients With Acute Decompensated Heart Failure and Pre-Existing Renal Dysfunction
| Autor: | Ronald M. Witteles, Kelly Matsuda, David P. Kao, Donald Schreiber, Randall H. Vagelos, Dianne Christopherson, Michael B. Fowler |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Nesiritide
medicine.medical_specialty Creatinine Acute decompensated heart failure business.industry Renal function medicine.disease Placebo Surgery law.invention chemistry.chemical_compound chemistry Randomized controlled trial law Anesthesia Heart failure medicine Cardiology and Cardiovascular Medicine business Kidney disease medicine.drug |
| Zdroj: | Journal of the American College of Cardiology. 50:1835-1840 |
| ISSN: | 0735-1097 |
| Popis: | Objectives Our purpose was to evaluate the impact of nesiritide on renal function in patients with acute decompensated heart failure and baseline renal dysfunction. Background Although nesiritide is approved for the treatment of acute decompensated heart failure, retrospective analyses have raised concerns that it may cause worsened renal function. To date, no randomized clinical trials have prospectively evaluated this issue. Methods Consecutive patients with acute decompensated heart failure and baseline renal dysfunction were enrolled in this randomized, double-blind, placebo-controlled clinical trial. Subjects were randomized to receive nesiritide (0.01 μg/kg/min with or without a 2-μg/kg bolus) or placebo (5% dextrose in water) for 48 h in addition to their usual care. Predefined primary end points of the trial were a rise in serum creatinine by ≥20% and change in serum creatinine. Results Seventy-five patients were enrolled (39 nesiritide, 36 placebo). The groups had similar baseline age (74.9 vs. 75.5 years, respectively), blood pressure (123/64 vs. 125/64 mm Hg) and serum creatinine (1.82 vs. 1.86 mg/dl). There were no significant differences in the incidence of a 20% creatinine rise (23% vs. 25%) or in the change in serum creatinine (−0.05 vs. +0.05 mg/dl). There were no significant differences in the secondary end points of change in weight (−2.19 vs. −1.58 kg), intravenous furosemide (125 vs. 107 mg), discontinuation of the infusion due to hypotension (13% vs. 6%), or 30-day death/hospital readmission (33% vs. 25%). Conclusions In this randomized, double-blind, placebo-controlled clinical trial, nesiritide had no impact on renal function in patients with acute decompensated heart failure. (BNP-CARDS trial; http://www.clinicaltrials.gov/ct/show/NCT00186329?order=1 ; NCT00186329 ) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|